Althea announces first phase of ADC offerings
Althea is expanding its biological drug product manufacturing operations to include highly active materials, such as Antibody Drug Conjugates (ADCs).
Archives for December 16, 2015
IPO ready BeiGene adopts GE tech for China cancer biologics plant
Nasdaq-bound Chinese biopharma BeiGene has chosen GE Healthcare’s Flexfactory platform for the monoclonal antibody (mAb) plant it is building in Suzhou.
AstraZeneca broadens JV with WuXi and eyes up China biologics plant
MedImmune has the option to acquire a Chinese biologics manufacturing facility for around $100m in an expansion of its joint venture with WuXi Apptech.